Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross SD IV Iron Policy Update | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - South DakotaPolicy 05.05.58

    Intravenous Iron

    Customize your policy alerts

    Sign up for blue cross blue shield - south dakota Policy 05.05.58 alerts

    Get alerted when Policy 05.05.58 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage and prior authorization for specified intravenous iron products, including preferred products and non-preferred products subject to a clinical exception process.

    Policy Summary
    PayerBlue Cross Blue Shield - South Dakota
    PolicyIntravenous Iron
    Policy CodePolicy 05.05.58
    Change TypeNo material change
    Effective DateJan 1, 2025
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and document a qualifying clinical exception before requesting a non-preferred product.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    4Preferred intravenous iron products
    1Targeted/non-preferred product
    2Clinical exception pathways
    7

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    HCPCS billing codes
    4Preferred products without prior authorization

    Non-Preferred Product Exception Criteria

    Non-preferred product exception criteria

    Coverage for a non-preferred product is provided when ONE of the following criteria is met.

    Qualifying exception

    • Clinical failure or intolerance: The member has had a documented inadequate response, intolerable adverse event, or a contraindication to the preferred products.
    • Continuation with benefit: The member is currently receiving therapy with a non-preferred product and is experiencing a positive therapeutic outcome.

    Procedures and Billing Codes

    Procedures and Billing CodesHCPCS
    J1437injection, ferric derisomaltose (Monoferric), 10 mg
    J1439injection, ferric carboxymaltose (Injectafer), 1 mg
    J1750injection, iron dextran (Infed), 50 mg
    J1756injection, iron sucrose (Venofer), 1 mg
    J2916injection, sodium ferric gluconate complex (Ferrlecit), 12.5 mg
    Q0138injection, ferumoxytol (Feraheme), 1 mg (non-esrd)
    Q0139injection, ferumoxytol (Feraheme), 1 mg (for esrd on dialysis)

    Prior Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization Required for Non-Preferred Therapy

    Prior authorization is required for treatment with a non-preferred intravenous iron product. Coverage may be approved through the clinical exception process when circumstances exclude use of the preferred product.

    • Applies to all members requesting treatment with a non-preferred product.
    • The review considers clinical circumstances and previous use of a product.
    Documentation Required

    Clinical Exception Documentation

    Document the clinical exception supporting use of the non-preferred product. The record must establish at least one qualifying circumstance or support continuation of an effective current non-preferred therapy.

    • Documented inadequate response to the preferred products.
    • Documented intolerable adverse event associated with the preferred products.

    Initial Non-Preferred Therapy

    Non-preferred product initial exception

    Coverage for initial treatment with a non-preferred product is provided when ONE of the following criteria is met.

    Clinical exception to preferred products

    • Failure, intolerance, or contraindication: The member has had a documented inadequate response, intolerable adverse event, or a contraindication to the preferred products.
    • Existing therapy with positive outcome: The member is currently receiving therapy with a non-preferred product and is experiencing a positive therapeutic outcome.

    Continuation of Non-Preferred Therapy

    Continuation of non-preferred therapy

    Coverage for continuation of a non-preferred product is provided when the following criterion is met.

    Positive therapeutic outcome: The member is currently receiving therapy with a non-preferred product and is experiencing a positive therapeutic outcome.
    Policy Summary
    PayerBlue Cross Blue Shield - South Dakota
    PolicyIntravenous Iron
    Policy CodePolicy 05.05.58
    Change TypeNo material change
    Effective DateJan 1, 2025
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and document a qualifying clinical exception before requesting a non-preferred product.
    SourceLink
    On This Page
    Non-Preferred Product Exception CriteriaProcedures and Billing CodesPrior Authorization and Documentation RequirementsInitial Non-Preferred TherapyContinuation of Non-Preferred Therapy
  1. Documented contraindication to the preferred products.
  2. Member is currently receiving a non-preferred product and experiencing a positive therapeutic outcome.
  3. Denial Risk

    Denial Risk When No Exception Is Met

    A non-preferred intravenous iron product may be denied when the submitted documentation does not demonstrate at least one qualifying exception criterion. Approval requires evidence that preferred therapy is unsuitable or that the member is having a positive therapeutic outcome on the current non-preferred product.

    • No qualifying inadequate response, intolerable adverse event, or contraindication is documented.
    • Current therapy circumstances do not show a positive therapeutic outcome.